News Releases Year None20242023202220212020201920182017 NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update Nov 25, 2024 NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel Nov 11, 2024 NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States Sep 25, 2024 NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024 Sep 14, 2024 NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study Aug 29, 2024 NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update Aug 15, 2024 NuCana to Present at the Jefferies Global Healthcare Conference May 30, 2024 NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit May 21, 2024 NuCana Reports First Quarter 2024 Financial Results and Provides Business Update May 16, 2024 NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement May 01, 2024 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel Nov 11, 2024
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States Sep 25, 2024
NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024 Sep 14, 2024